CEO Mark Lappe purchased $585k of INBX stock at $99.29, signaling confidence in the company's oncology pipeline just days after positive Phase 2 data was released. This insider buying comes as the stock has rallied nearly 29% over the last 30 days.
Price context
The stock is down 7.92% over the last 5 days but remains up 27.72% over the last 90 days, trading 25.47% below its 52-week high of $153.68.
Catalysts to watch
1) Upcoming FDA interactions and Biologics License Application submission for ozekibart in colorectal cancer (May 2, 2026 news). 2) Merck collaboration expansion for INBRX-106 in head and neck cancer (May 12, 2026 news). 3) Continued Phase 2 data readouts for INBRX-106 in head and neck cancer.
Risks
The stock is highly volatile with a beta of 3.671 and currently trades at a forward P/E of -13.05, indicating significant uncertainty regarding profitability.
AI-generated context from public data. Not investment advice. Verify before trading.